The Chinese Pharmaceutical market is expected to grow at a CAGR of 12.3% in the second half of the forecast period. The Chinese Pharmaceutical market reached $145.4bn in 2016, dominated by the Cardiovascular therapy area which held 13.6% share of the market.
How this report will benefit you Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 253-page report you will receive 68 tables and 90 figures– all unavailable elsewhere.
The 253-page report provides clear detailed insight into the Chinese Pharmaceutical market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Chinese Pharmaceutical market forecasts from 2017-2027
• This report also breaks down the revenue forecast for the Chinese Pharmaceutical market by therapy area: – Cardiovascular: including specific revenue forecasts for Hypertension and Dyslipidaemia – Anticancer – Infectious Diseases – Diabetes – Respiratory: including specific revenue forecasts for Asthma and COPD – Central Nervous System: including specific revenue forecasts for Antidepressants – Autoimmune – Others
This report lists and discusses the domestic pharmaceutical companies that dominate each submarket. Moreover, this report discusses the drivers and restraints of each submarket.
• This report also breaks down the revenue forecast for the Chinese Pharmaceutical market by leading product class: – Small Molecules: further broken down into Generics Drugs and Branded Drugs – Traditional Chinese Medicine – Biologics: further broken down into Biologics (branded), Vaccines and Biosimilars
This report lists and discusses the domestic pharmaceutical companies that dominate each submarket. Moreover, this report discusses the drivers and restraints of each submarket.
• This report also breaks down the revenue forecast for the Chinese Pharmaceutical market byleading type of drug: – Generic Prescription Drugs – Over-the-Counter (OTC) Drugs – Patented Prescription Drugs
This report lists and discusses the domestic pharmaceutical companies that dominate each submarket.
• This report also breaks down the revenue forecast for the Chinese Pharmaceutical market bysales channel: – Hospitals – Retail Pharmacies – Grassroots Clinics
This report lists and discusses the domestic pharmaceutical companies that dominate each submarket.
• This report discusses trends in the industry and assesses strengths and weaknesses, as well as opportunities and threats (SWOT) that influence the Chinese Pharmaceutical Market. It also analyses social, technological, economic and political factors (STEP) that influence the Chinese Pharmaceutical Market
• Our study ranks and provides 2016 revenues as well as market share of the top 50 domestic Chinese Pharmaceutical companies and top 10 Multinational Pharmaceutical Companies that are the major players in the Chinese Pharmaceutical Market
• Our study lists and discusses the leading domestic and multinational Contract Research Organizations (CRO) that dominate the Chinese Pharmaceutical Market.
Visiongain’s study is intended for anyone requiring commercial analyses for the Chinese Pharmaceutical market. You find data, trends and predictions.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 The Chinese Pharmaceutical Market, 2017-2027 1.2 Chinese Pharmaceutical Market: Segmentation, 2017 1.3 Why You Should Read This Report 1.4 How This Report Delivers 1.5 Main Questions Answered by This Analytical Study 1.6 Who is This Report For? 1.7 Methods of Research and Analysis 1.8 Frequently Asked Questions (FAQ) 1.9 Associated Visiongain Reports 1.10 About Visiongain
2. Chinese Healthcare: Overview, 2017 2.1 China: Demographic Indicators Overview, 2017 2.2 Chinese Healthcare System: Overview, 2017 2.3 Analysis of China’s Healthcare Expenditure 2.4 The Chinese System: Who Really Pays the Bill? 2.5 State Bodies Regulating the Chinese Pharmaceutical Market 2.6 Healthy China 2020: The Government’s Long-term Plan 2.7 Analysis of the Potential of ‘Healthy China Initiative’, 2017 2.8 The Big Debate About Healthcare Funding
3. Chinese Pharmaceutical Market: Discussions and Predictions, 2017-2027 3.1 Chinese Pharmaceutical Market: The Second Biggest Market in the World, 2016 3.2 Chinese Pharmaceutical Market: Overall Revenue Forecast, 2017-2027
4. Medical Treatment Needs in China, 2017-2027 4.1 Disease Prevalence in China, 2017-2027 4.2 Disease Mortality Rates in China 4.2.1 Top 5 Broad Causes of Death in China
5. Chinese Pharmaceutical Market: Leading Therapeutic Areas, 2017-2027 5.1 Leading Therapeutic Areas in the Chinese Pharmaceutical Market: Overview, 2016 5.2 Chinese Pharmaceutical Market: Leading Therapeutic Areas Forecasts, 2017-2027 5.3 Chronic Diseases Overtook the Infectious Diseases Segment, 2017-2027 5.4 Expanding China’s EDL: New Blockbusters for 2017 5.5 Cardiovascular Therapeutic Segment: Overview, 2017 5.5.1 Cardiovascular Drugs Market: Forecast, 2017-2027 5.5.2 Hypertension in China Reaches Unprecedented Levels 5.5.3 Chinese Hypertension Drugs Market Continuing to Thrive: Forecast, 2017-2027 5.5.4 Chinese Hypertension Drugs Market: Leading Products 5.5.5 Treatment of Chinese Hypertensive Patients 5.5.6 Dyslipidaemia: Overview of China’s Most Prevalent Disease 5.5.7 Treatment of Dyslipidaemia Affected by Reimbursement Issues 5.5.8 Chinese Dyslipidaemia Market Prospects: Forecast, 2017-2027 5.5.9 Chinese Cardiovascular Disease Segment: Major Focus of Western Companies 5.5.10 Big Pharma Companies Dominate the Chinese Hypertension Drugs Market 5.5.11 Increasing Domestic Company Presence in the Cardiovascular Therapeutic Segment 5.5.12 Drivers and Restraints for the Chinese Cardiovascular Drugs Market, 2017 5.6 Anticancer Therapeutic Segment: Overview, 2017 5.6.1 Anticancer Drugs will be the Largest Segment of the Chinese Pharmaceutical Market by 2027: Forecast, 2017-2027 5.6.2 Cancer Incidence Boosts the Eminence of China’s Anticancer Drugs Market 5.6.3 Targeted Anticancer Therapeutics Making Progress in China 5.6.4 Chinese Pharma Companies Focusing on Anticancer Drugs 5.6.5 Eli Lilly and Innovent Biologics’ Strategic Alliance: New Big Player in China’s Anticancer Market? 5.6.6 Improved Healthcare Coverage for Cancer Patients Promises Strong Revenue Stream from Anticancer Drugs 5.6.7 Marketing Innovative Anticancer Drug in China – Example from Roche 5.6.8 Negative Impact of Late Cancer Diagnosis 5.6.9 Cost of Treatment Critical for the Choice of Anticancer Medicine 5.6.10 Tailored Anticancer Treatment for the Chinese Market - Notable Companies and their Developments 5.6.11 Biomarker Testing in China – What Improvement is Possible? 5.6.12 Drivers and Restraints for the Anticancer Drugs Segment, 2017 5.7 Infectious Disease Therapeutics: Overview, 2017 5.7.1 Infectious Disease Drugs Market: Forecast, 2017-2027 5.7.2 What Makes China Prominent for Antibiotics Use: Analysis of Cephalosporin, 2016 5.7.3 China’s Infectious Disease Market Dominated by Domestic Companies 5.7.4 Antibiotics Over-use Reported in China: Causes and Results 5.7.5 HIV and Hepatitis in China: Viread Added to EDL in 2017 5.7.6 Hepatitis C Drug Challenges 5.7.7 Drivers and Restraints for the Infectious Diseases Pharma Segment, 2017 5.8 Diabetes Therapeutic Segment: Overview, 2017 5.8.1 Diabetes Drugs Market: Forecast, 2017-2027 5.8.2 Multinational Companies in the Chinese Diabetes Drug Market: Overview and Analysis, 2017 5.8.3 Domestic Companies Competing in the Chinese Diabetes Drug Market 5.8.4 Diabetes in China: Challenges and Opportunities 5.8.5 Drivers and Restraints for the Diabetes Drugs Segment, 2017 5.9 Respiratory Therapeutic Segment: Overview, 2017 5.9.1 Respiratory Disease Drugs Market: Forecast, 2017-2027 5.9.2 Chinese COPD Market: How Profitable Could It Be? 5.9.3 Chinese COPD Treatments Market: Predicted Revenue Increase – Forecast, 2017-2027 5.9.4 Chinese Asthma Drugs Market to Give Dependable Growth: Forecast, 2017-2027 5.9.5 Domestic Respiratory Drug Producers 5.9.6 Leading Respiratory Disease Drugs in China 5.9.7 AstraZeneca Sustains Market Penetration through Collaboration and Research 5.9.8 Drivers and Restraints for the Respiratory Diseases Segment, 2017 5.10 Central Nervous System (CNS) Therapeutics: Overview, 2017 5.10.1 CNS Drugs Market: Forecast, 2017-2027 5.10.2 By 2027, 8 Million People in China will Suffer from Depression 5.10.3 Depression Drugs Market in China will Reach a 25% Annual Growth Rate: Forecast, 2017-2027 5.10.4 Domestic Companies in China’s CNS Disorders Market 5.10.5 China’s Aging Population: Driver for the CNS Segment 5.10.6 Rise of Dementia and Alzheimer’s Disease Presents Strong Market Opportunity 5.10.7 High Demand for Pain Relief Medicines in China 5.10.8 Drivers and Restraints for the CNS Drugs Segment, 2017 5.11 Immunomodulators: Overview, 2017 5.11.1 Autoimmune Drugs Market: Forecast, 2017-2027 5.11.2 Notable Chinese Companies in the Immunomodulators Market 5.11.3 Challenges Erode the Immunomodulators Market’s Potential 5.11.4 Immunomodulator Treatments to Gain Momentum in China 5.11.5 Drivers and Restraints for the Autoimmune Drugs Segment, 2017
6. Chinese Pharmaceutical Market: Leading Product Classes, 2017-2027 6.1 Product Classes in the Chinese Pharmaceutical Market: Overview, 2016 6.2 Chinese Pharmaceutical Market: Product Classes Forecasts, 2017-2027 6.3 Small Molecules: Overview, 2017 6.3.1 Chinese Small Molecule Drugs Market: Forecast, 2017-2027 6.3.2 Generics: Growth Engine for the Small Molecules Segment 6.3.3 Healthcare Reform Provides Opportunities for Original-Branded and Generic Drugs 6.3.4 Drivers and Restraints for the Small Molecule Treatments Market in China, 2017 6.4 Traditional Chinese Medicine (TCM): Overview, 2017 6.4.1 Traditional Chinese Medicine Market: Forecast, 2017-2027 6.4.2 Investments in TCM Development: Analysis of China’s TCM Market, 2017 6.4.3 Expansion of the TCM Market 6.4.4 Leading Chinese Companies in the TCM Segment, 2017 6.4.5 Drivers and Restraints for the Traditional Chinese Medicines Market, 2017 6.5 Chinese Biological Drugs Market: Overview, 2016 6.5.1 Chinese Biologics Market: Forecasts, 2017-2027 6.5.2 Branded Biologics Perform Well in China: Forecast, 2017-2027 6.5.3 Biomedicines Set for Strategic Growth: Analysis of China’s Fastest Growing Product Class, 2017 6.5.4 Roche Finding a Way Forward in China with Branded Biologics 6.5.5 Chinese Vaccines Market: Overview, 2016 6.5.6 China: The World’s Fifth Largest Vaccine Market 6.5.7 Chinese Vaccines Segment Loses Share: Forecast, 2017-2027 6.5.8 Companies Dominating the Vaccines Market in China 6.5.9 Domestic Manufacturer Supplies 80% of Vaccines in China 6.5.10 Multinational Companies Compete for a Share of the Chinese Vaccines Market 6.5.11 Hepatitis B Vaccine in China – a Story of Success 6.5.12 Chinese Biosimilars Market: Overview, 2016 6.5.13 Chinese Biosimilars Market: Forecast, 2017-2027 6.5.14 A Boost for Biosimilars? Pfizer Set up a New Chinese Manufacturing Facility 6.5.15 Chinese Biosimilar Development Guidelines Released in 2015 6.5.16 Leading Chinese Biosimilar Manufacturers 6.5.17 Market Access for Biosimilars: Critical to Leverage Opportunities in China 6.5.18 Drivers and Restraints of the Chinese Biologics Market
7. Chinese Pharmaceutical Market: Leading Drug Types, 2017-2027 7.1 Drug Types in the Chinese Market: Overview, 2016 7.2 Growth Forecasts for Leading Drug Types in China, 2017-2027 7.3 Generic Drugs Dominate the Chinese Pharmaceutical Market 7.3 Generic Prescription Drugs Market in China: Forecast, 2017-2027 7.3.1 Chinese Pharmaceutical Market Structure Favours Generics’ Sales 7.3.2 Which Drugs Benefit More from the Government’s Healthcare Reform: Original-Patented or Generic? 7.3.3 Many Chinese Patients Favour Branded Generics 7.3.4 AstraZeneca and Pfizer: Leaders in the Chinese Branded Generics Market 7.4 Chinese Over-the-Counter Medicines Market: Forecast, 2017-2027 7.4.1 Chinese OTC Drugs Segment: Insights and Analysis of the Market’s Potential, 2016 7.4.2 China: The World’s Biggest OTC Pharmaceuticals Market 7.4.3 Leading Domestic Companies in the Chinese OTC Market, 2017 7.4.4 Bayer: The Biggest Multinational Player in China’s OTC Market 7.5 Chinese Patented Prescription Drugs Market: Forecast, 2017-2027 7.5.1 Online Sales Prohibited in 2016: A Big Blow to the Market?
8. Chinese Pharmaceutical Market: Sales Channels, 2017-2027 8.1 Chinese Pharmaceutical Market: Sales Channels Overview and Value, 2016 8.2 Chinese Pharmaceutical Market: Sales Channels Forecasts, 2017-2027 8.3 Only Five Domestic Companies Have a Sizable Share of the Chinese Pharma Distribution Market 8.4 Chinese Distribution Channels are Highly Fragmented Compared to Western Counterparts 8.5 Chinese Distribution Channels: Why Consolidation is Essential? 8.6 Shift Towards Consolidation within the Distribution Chain: Key Market Developments 8.7 China’s Drugs Distribution Environment: Issues and Challenges 8.8 Chinese Distribution Value Chain Follows a Complex Model 8.9 Chinese Pharmaceutical Distribution Network Comprises the World’s Largest Sales Force 8.10 Bribery Penalties: Indication of China’s Changing Pharmaceutical Distribution Practices 8.11 Hospital Sales Channels: Forecast, 2017-2027 8.11.1 Hospitals: Foundation of the Chinese Healthcare System 8.11.2 Chinese Public Hospitals: Healthcare Reform’s Priority 8.11.3 How does the Medicines Mark-up Ban Affect Hospitals’ Revenues? 8.12 Retail Pharmacies Channels: Forecast, 2017-2027 8.12.1 Difficulties in Retail Pharmacy Market Estimates 8.12.2 Online Sale Prohibition May Affect the Distribution of Revenue Within the Market 8.13 Grassroots Clinics’ Sales Channels: Forecast, 2017-2027 8.13.1 Rural Investment Will Facilitate Drug Sales Growth in Grassroots Clinics 8.14 Other Sales Channels: Forecast, 2017-2027 8.14.1 Other Sales Channels: The Grey Pharmaceuticals in China
9. Leading Companies in the Chinese Pharmaceuticals Market, 2016 9.1 Top 50 Domestic Chinese Pharmaceutical Companies, 2016 9.2 China’s Pharma is Highly Fragmented Compared to Other Prominent Markets 9.3 Leading Chinese Contract Research Organizations 9.4 Leading Multinational Companies in the Chinese Pharmaceutical Market: Strategies that Win, 2017 9.4.1 MNC Revenue and Market Share Estimates, 2016 9.4.2 AstraZeneca and Pfizer: Leaders in the Chinese Branded Generics Segment 9.4.3 Bayer – Exceeds $3bn of Pharma Sales in China 9.4.4 Pfizer’s Strategic Approach in China – Does it Work? 9.4.5 Multinational Contract Research Organizations in China 9.5 New Policies Shift the Market Dynamics for Leading Players 9.6 Emerging Strategies to Boost Drug Sales and Comply with Regulations 9.7 What is Next in China for Multinational Pharma Companies? 9.8 Drivers and Restraints for Big Pharma’s Sales Growth in China, 2017
10. Qualitative Analysis of the Chinese Pharmaceutical Market, 2017 10.1 Strengths: Increasing Investment in the Healthcare System 10.1.1 As the Disease Burden Grows, So Does GDP 10.1.2 Chinese Pharmaceutical Market Still Has Untapped Potential 10.1.3 Progressive Urbanization Continues to Drive Healthcare Spending 10.1.4 New Policies Recognize the Importance of IP 10.1.5 Research Hub for Asia Pacific and Beyond 10.2 Weaknesses: Imbalance of Resources and Quality Challenges 10.2.1 Healthcare Quality Issues Hit the Chinese Pharmaceutical Market 10.2.2 Highly Fragmented Pharmaceutical Market 10.2.3 Reimbursement and Market Access 10.2.4 Limited First-Class Laboratory Facilities Reported 10.2.5 Regulations and Clinical Trial Research 10.3 Opportunities: Quickly Emerging Volume Growth 10.3.1 Tailored Strategies to Meet the Chinese Pharma Market’s Need 10.3.2 Portfolio Diversification Matters 10.3.3 Enhancing Consolidation Activities 10.3.4 Innovative Biotechnology Sector 10.3.5 Liberal Regulations on Stem Cells Research 10.4 Threats: What if Things Go Wrong in China? 10.4.1 Strong Government Intervention 10.4.2 Anhui Model and its Results 10.5 Social Forces: The Increasing Power of China’s Demographics 10.5.1 The Ageing Dragon 10.5.2 The Obesity Epidemic 10.5.3 Social Changes and Their Effect on China’s Shifting Medical Treatment Patterns 10.6 Technological Factors: Embracing Technology and Increasing R&D Capabilities 10.6.1 National Database and Telemedicine: New Trends Shaping the Industry 10.6.2 Developing China’s R&D Capabilities through Technology 10.6.3 China Has the World’s Largest and Most Affordable Genomic Sequencing Facilities 10.7 Economic Factors: Economic Growth Closely Related to the Chinese Pharmaceutical Market Growth 10.7.1 China’s Rise as an Economic Superpower 10.7.2 Underlying Problems of China’s Economic Growth 10.7.3 How Many Five-Year Plans Will Follow? 10.8 Political: The Chinese Government Possesses the Ultimate Power
11. Conclusions 11.1 China’s Healthcare Reform: Crucial Factor for Pharmaceutical Market Growth 11.2 China: The Country Driving Growth for the World’s Pharmaceutical Market, 2017-2027 11.3 Cancer Will Form a Main Therapeutic Segment in the Chinese Pharmaceutical Market in 2027 11.4 Generic and OTC Drugs Set to Remain the Main Product Types, but Patented Drugs Will Experience Momentum 11.5 Pharmacy Sales are the Next Big Market Opportunity in China 11.6 Domestic Companies Still Dominate the Chinese Pharma Market, Amid Increasing Competition from MNCs 11.7 Concluding Thoughts on the Research and Analysis
Appendices Visiongain Report Sales Order Form About Visiongain Associated Visiongain Reports Visiongain report evaluation form
List of Tables Table 2.1 China: Demographic Indicators, 2006-2016 Table 2.2 Healthcare Expenditure: Leading Markets and BRIC Countries, Total (%) of GDP, 2006-2014 Table 2.3 Out-of-pocket Health Expenditures in China: (%) of Private Spending on Healthcare, 2006-2014 Table 2.4 Chinese Institutions Regulating the Pharmaceutical and Healthcare Industries in China, 2017 Table 3.1 Chinese Pharmaceutical Market Overall Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2017-2027 Table 4.1 Top 5 Causes of Death per (000s) in China’s Urban and Rural Areas, 2016 Table 5.1 Chinese Pharmaceutical Market by Therapy Area: Market Size ($bn), Market Share (%), 2016 Table 5.2 Chinese Pharmaceutical Market by Therapy Area: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 5.3 Chinese Pharmaceutical Market by Therapy Area: Market Share Forecast (%), 2017-2027 Table 5.4 Selected High Profile Drugs: China’s Essential Drugs List Table 5.5 Chinese Cardiovascular Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 5.6 Chinese Hypertension Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2017-2027 Table 5.7 Chinese Hypertension Market by Drug Class: Market Size ($bn), Market Share (%), 2016 Table 5.8 Chinese Dyslipidaemia Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2017-2027 Table 5.9 Top Companies in the Chinese Hypertension Market: Revenue ($bn), Market Share (%), 2016 Table 5.10 Leading Domestic Chinese Cardiovascular Drug Manufacturers and Their Activities, 2017 Table 5.11 Chinese Anticancer Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 5.12 Selected Domestic Chinese Anticancer Drug Manufacturers and Their Activities, 2017 Table 5.13 Chinese Infectious Disease Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 5.14 Chinese Infectious Disease Drugs Market by Drug Class: Market Size ($bn), Market Share (%), 2016 Table 5.15 Domestic Antibacterial Drug Manufacturers and Their Activities, 2017 Table 5.16 Chinese Diabetes Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 5.17 Selected Domestic Chinese Diabetes Drug Manufacturers and Their Activities, 2017 Table 5.18 Chinese Respiratory Disease Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 5.19 Chinese COPD Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2017-2027 Table 5.20 Chinese Asthma Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), CAGR (%), 2017-2027 Table 5.21 Selected Domestic Companies in the Respiratory Market and Their Activities, 2017 Table 5.22 Chinese Respiratory Drug Market by Product Class: Sales ($bn), Market Share (%), 2016 Table 5.23 Chinese CNS Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 5.24 Chinese Antidepressants Market Forecast: Market Size ($bn), Annual Growth Rate (%), 2017-2027 Table 5.25 Selected Domestic Companies in the CNS Market and Their Activities, 2017 Table 5.26 Chinese Autoimmune Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 5.27 Selected Chinese Immunomodulator Drug Companies and Their Activities, 2017 Table 6.1 Chinese Pharmaceutical Market by Product Class: Market Size ($bn), Market Share (%), 2016 Table 6.2 Chinese Pharmaceutical Market by Product Class: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 6.3 Chinese Small Molecule Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 6.4 Chinese Small Molecule Drugs Market by Product Type: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 6.5 Traditional Chinese Medicine Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 6.6 Selected TCM Manufacturers and their Activities, 2017 Table 6.7 Chinese Biological Drugs Market by Product Type: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 6.8 Chinese Branded Biologics Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 6.9 Chinese Vaccines Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 6.10 Chinese Biosimilars Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 6.11 Selected Chinese Biosimilar Manufacturers and Their Product Lines, 2017 Table 7.1 Chinese Pharmaceutical Market by Drug Type: Market Size ($bn), Market Share (%), 2016 Table 7.2 Chinese Pharmaceutical Market by Drug Type: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 7.3 Chinese Generic Prescription Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 7.4 Chinese Over-the-Counter Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 7.5 Selected Chinese OTC Drug Manufacturers and Their Activities, 2017 Table 7.6 Chinese Patented Prescription Drugs Market Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 8.1 Hospital Channels Market Size ($bn), Market Share (%), 2016 Table 8.2 Chinese Pharmaceutical Market by Sales Channel: Market Size ($bn), Market Share (%), 2016 Table 8.3 Chinese Pharmaceutical Market by Sales Channel: Forecast Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 8.4 Chinese Hospital Sales of Pharmaceuticals Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 8.5 Chinese Retail Pharmacy Sales of Pharmaceuticals Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 8.6 Chinese Grassroots Clinics Sales of Pharmaceuticals Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 8.7 Chinese Pharmaceuticals Sales Through Other Channels Forecast: Market Size ($bn), Annual Growth Rate (%), Market Share (%), CAGR (%), 2017-2027 Table 9.1 Top 50 Domestic Chinese Pharmaceutical Companies: Rank (1-25), Revenue ($bn), Market Share (%), 2016 Table 9.2 Top 50 Domestic Chinese Pharmaceutical Companies: Rank (26-50), Revenue ($bn), Market Share (%), 2016 Table 9.3 Selected Domestic Contract Research Organizations and Their Activities, 2017 Table 9.4 Selected Multinational Pharmaceutical Companies in the Chinese Market and Their Activities, 2017 Table 9.5 Selected Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (Continued), 2017 Table 9.6 Selected Multinational Pharmaceutical Companies in the Chinese Market and Their Activities (Continued), 2017 Table 9.7 Top 10 Multinational Pharmaceutical Companies in the Chinese Pharmaceutical Market: Revenue ($bn), Market Share (%), 2016 Table 11.1 Summary of the Chinese Pharmaceutical Market by Product Class: Market Size ($bn), Market Share (%), CAGR (%), 2016, 2022, 2026 Table 11.2 Summary of the Chinese Pharmaceutical Market by Therapy Class: Market Size ($bn), Market Share (%), CAGR (%), 2016, 2022, 2027 Table 11.3 Summary of Chinese Pharmaceutical Sales Channels: Market Size ($bn), Market Share (%), CAGR (%), 2016, 2022, 2027
List of Figures Figure 1.1 Chinese Pharmaceutical Market Segmentation, 2017 Figure 2.1 Healthcare Expenditure Per Capita PPP: Leading Markets and BRIC Countries, ($bn) Figure 2.2 Out-of-pocket Health Expenditures in China: (%) of Private Spending on Healthcare, 2006-2014 Figure 3.1 Chinese Pharmaceutical Market: Value Chain, 2017 Figure 3.2 Chinese Pharmaceutical Market Forecast: Market Size ($bn), 2017-2027 Figure 3.3 Chinese Pharmaceutical Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 4.1 Top 5 Broad Causes of Death in China Urban Areas, 2016 Figure 4.2 Top 5 Broad Causes of Death in China Rural Areas, 2016 Figure 5.1 Chinese Pharmaceutical Market by Therapy Area: Market Size ($bn), 2016 Figure 5.2 Chinese Pharmaceutical Market by Therapy Area: Market Share (%), 2016 Figure 5.3 Chinese Pharmaceutical Market by Therapy Area: Market Share (%), 2022 Figure 5.4 Chinese Pharmaceutical Market by Therapy Area: Market Share (%), 2027 Figure 5.5 Chinese Cardiovascular Disease Market: Segmentation by Drug Class, 2017 Figure 5.6 Chinese Cardiovascular Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.7 Chinese Cardiovascular Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.8 Chinese Hypertension Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.9 Chinese Hypertension Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.10 Chinese Hypertension Market by Drug Class: Market Share (%), 2016 Figure 5.11 Chinese Dyslipidaemia Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.12 Chinese Cardiovascular Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.13 Chinese Cardiovascular Drugs Market: Drivers and Restraints, 2017-2027 Figure 5.14 Chinese Anticancer Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.15 Chinese Anticancer Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.16 Chinese Anticancer Drugs Market: Drivers and Restraints, 2017-2027 Figure 5.17 Chinese Infectious Disease Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.18 Chinese Infectious Disease Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.19 Chinese Antibacterial Drugs Market by Drug Class: Market Share (%), 2016 Figure 5.20 Chinese Infectious Disease Drugs Market: Drivers and Restraints, 2017-2027 Figure 5.21 Chinese Diabetes Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.22 Chinese Diabetes Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.23 Chinese Diabetes Drugs Market: Drivers and Restraints, 2017-2027 Figure 5.24 Chinese Respiratory Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.25 Chinese Respiratory Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.26 Chinese COPD Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.27 Chinese COPD Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.28 Chinese Asthma Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.29 Chinese Asthma Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.30 Chinese Respiratory Disease Drugs Market: Drivers and Restraints, 2017-2027 Figure 5.31 Chinese CNS Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.32 Chinese CNS Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.33 Chinese Antidepressant Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.34 Chinese Antidepressant Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.35 Chinese CNS Drugs Market: Drivers and Restraints, 2017-2027 Figure 5.36 Chinese Autoimmune Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 5.37 Chinese Autoimmune Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 5.38 Chinese Autoimmune Drugs Market: Drivers and Restraints, 2017-2027 Figure 6.1 Chinese Pharmaceutical Market by Product Class: Market Size ($bn), 2016 Figure 6.2 Chinese Pharmaceutical Market by Product Class: Market Size ($bn), 2017-2027 Figure 6.3 Chinese Pharmaceutical Market by Product Class: Market Size (%), 2016 Figure 6.4 Chinese Small Molecule Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 6.5 Chinese Small Molecule Drugs Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 6.6 Chinese Small Molecule Drugs Market: Drivers and Restraints, 2017-2027 Figure 6.7 Traditional Chinese Medicine Market Forecast: Market Size ($bn), 2017-2027 Figure 6.8 Traditional Chinese Medicine Market Forecast: Annual Growth Rate (%), 2017-2027 Figure 6.9 Traditional Chinese Medicine Market: Drivers and Restraints, 2017-2027 Figure 6.10 Chinese Biologics Market Forecast: Market Size ($bn), 2017-2027 Figure 6.11 Chinese Biologics Market Forecast: Annual Growth (%), 2017-2027 Figure 6.12 Chinese Branded Biologics Market Forecast: Market Size ($bn), 2017-2027 Figure 6.13 Chinese Branded Biologics Market Forecast: Annual Growth (%), 2017-2027 Figure 6.14 Chinese Vaccines Market Forecast: Market Size ($bn), 2017-2027 Figure 6.15 Chinese Vaccines Market Forecast: Annual Growth (%), 2017-2027 Figure 6.16 Chinese Biosimilars Market Forecast: Market Size ($bn), 2017-2027 Figure 6.17 Chinese Biosimilars Market Forecast: Annual Growth (%), 2017-2027 Figure 6.18 Chinese Biologics Market: Drivers and Restraints, 2017-2027 Figure 7.1 Chinese Pharmaceutical Market by Drug Type: Market Size ($bn), 2016 Figure 7.2 Chinese Pharmaceutical Market by Drug Type: Market Share (%), 2016 Figure 7.3 Chinese Generic Prescription Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 7.4 Chinese Generic Prescription Drugs Market Forecast: Annual Growth (%), 2017-2027 Figure 7.5 Chinese Over-the-Counter Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 7.6 Chinese Over-the-Counter Drugs Market Forecast: Annual Growth (%), 2017-2027 Figure 7.7 Chinese Patented Prescription Drugs Market Forecast: Market Size ($bn), 2017-2027 Figure 7.8 Chinese Patented Prescription Drugs Market Forecast: Annual Growth (%), 2017-2027 Figure 8.1 Hospital Channels Market Size ($bn), Market Share (%), 2016 Figure 8.2 Chinese Pharmaceutical Market by Sales Channel: Market Size ($bn), 2016 Figure 8.3 Chinese Pharmaceutical Market by Sales Channel: Market Share (%), 2016 Figure 8.4 Chinese Pharmaceutical Market by Sales Channels: Revenue Forecasts ($bn), 2017-2027 Figure 8.5 Fragmented Nature of the Chinese Pharmaceutical Distribution Market: Market Share (%) by Revenue ($bn) for the Leading Five Distributors, 2016 Figure 8.6 Chinese Hospital Sales of Pharmaceuticals Market Forecast: Market Size ($bn), 2017-2027 Figure 8.7 Chinese Hospital Sales of Pharmaceuticals Forecast: Annual Growth (%), 2017-2027 Figure 8.8 Chinese Retail Pharmacy Sales of Pharmaceuticals Forecast: Market Size ($bn), 2017-2027 Figure 8.9 Chinese Retail Pharmacy Sales of Pharmaceuticals Forecast: Annual Growth (%), 2017-2027 Figure 8.10 Chinese Grassroots Clinics Sales of Pharmaceuticals Forecast: Market Size ($bn), 2017-2027 Figure 8.11 Chinese Grassroots Clinics Sales of Pharmaceuticals Forecast: Annual Growth (%), 2017-2027 Figure 8.12 Chinese Pharmaceuticals Sales Through Other Channels Forecast: Market Size ($bn), 2017-2027 Figure 8.13 Chinese Pharmaceuticals Sales Through Other Channels Forecast: Market Size ($bn), 2017-2027 Figure 9.1 Top 10 Multinational Pharmaceutical Companies in the Chinese Pharmaceutical Market: Revenue ($bn) Chinese Pharma Market, 2016 Figure 9.2 Chinese Pharmaceutical Market: Drivers and Restraints for MNCs’ Growth, 2017-2027 Figure 11.1 Summary of the Chinese Pharmaceutical Market by Product Class: Market Size ($bn), 2016, 2022, 2027 Figure 11.1 Summary of the Chinese Pharmaceutical Market by Therapy Class: Market Size ($bn), 2016, 2022, 2027 Figure 11.2 Summary of the Chinese Pharmaceutical Sales Channels: Market Size ($bn), 2016, 2022, 2027
3SBio Acambis Agilent Alibaba Group Alliance Boots Amerisource-Bergen Amgen Anhui Anke Biotech AppTech Laboratory Services Asian Cancer Research Group Astellas AstraZeneca Asymchem Laboratories AXM Pharma Baxter Bayer Bayer Healthcare BeiGene Beijing Four Rings Bio-pharmaceutical Beijing Genomics Institute Beijing Kexing Bioproducts Beijing Key Yuan Xinhai Pharmaceutical Beijing SL Pharmaceutical Beijing Taiyang Beijing Tiantan Biological Products Beijing Tong Ren Tang Bio-Bridge Science BiODura Bloomberg Boehringer Ingelheim Bristol-Myers Squibb Buchang Pharma Cardinal Health CASiGEN Pharma Celgene Celsion Corp Changzhou Qianhong Biopharma Chemizon (Beijing) Pharma-Tech Chengdu Di'ao Pharmaceutical Group Chengdu Institutes of Biological Products Chiesi Edding Hong Kong Limited Chi-Med China Chemical & Pharmaceutical Group China National Accord China National Biotec Group China National Pharmaceutical Group China NT Pharma Group China Pharmaceutical Commerce Association China Pharmaceutical Quality Management Association China Resources Double-Crane Pharmaceuticals China Resources Sanjiu Medical China Shineway Pharmaceutical China Traditional Chinese Medicine Co. ChinaBio Group ChinaGate Chonqqing Taiji Industry Cipla Consun Pharmaceutical Group Cord Blood America Covance CSPC Pharmaceutical Group Daan Gene Daiichi Sankyo Dalian Hissen Bio-Pharm Dawnrays Pharmaceutical Holdings Dihon Pharmaceutical Group Dongsheng Pharmaceutical Dr. Reddy’s Laboratories Egret Eisai Eli Lilly Excel PharmaStudies FeRx Incorporated Financial Times Foshan City Furen Pharmaceutical Group Gan & Lee Pharmaceutical Genentech GeneScience Pharmaceuticals Gilead Sciences GlaxoSmithKline Goldman Sachs Guangdong BeiKang Pharmaceutical Guangdong Techpool Guangxi Wuzhou Zhongheng Group Guangzhou Medical University Guangzhou Pharma Guangzhou Pharmaceutical Corporation Guizhou Baiqiang Pharmaceutical Hangzhou East China Pharmaceutical Group Hangzhou Jiuyuan Gene Engineering Hangzhou Tigermed Consulting Hangzhou Zhongmei Huadong Pharmaceutical Harbin Pharmaceutical Group Harbin Tri-Lion Pharmaceutical Harvard University HD Biosciences Henan Lingrui Pharmaceutical Hengrui Henlius Biopharmaceuticals HitGen Hua Medicine Huadong Medicine Hualan Biological Engineering Hualida Biotech Hutchinson Whampoa Hutchison MediPharma i3 Research ICON Inner Mongolia Yili Energy Innovent Biologics JD.com (Jindong Mall) JHL Biotech Jiangsu Chia-tai Tianqing Pharmaceutical Jiangsu Hansen Pharmaceutical Jiangsu Hansoh Pharmaceutical Jiangsu Hengrui Medicine Jiangsu Nhwa Pharmaceutical Jilin Extrawell Changbaishan Jilin Province Huinan Changlong Jinling Pharmaceutical Johnson & Johnson Joincare Pharma JOINN Laboratories Kangmei Pharmaceutical KPC Pharmaceuticals Lepu Medical Livzon Pharmaceutical Group Lundbeck Lundbeck Institute Massachusetts Institute of Technology McKesson Merck & Co. Merck Sharp & Dohme Microport Medical Mycenax Mylan Nanjing Kanghai Pharmaceutical Nanjing Pharmaceutical Factory Nestle Health Sciences Nestle SA Newsummit Biopharma North China Pharmaceutical Group Northeast Pharmaceutical Group (NEPG) Novartis Novast Laboratories Novo Nordisk Oncobiologics Otsuka Pfizer Pharmaceutical Product Development LLC Pharmaron PKU Healthcare Group Qilu Pharmaceutical Quintiles Roche Sanofi Schering-Plough Servier Shandong Dong-E E-Jiao Shandong Kexing Bioproducts Shanghai Celgen Bio-Pharmaceutical Shanghai Charity Foundation Shanghai CP Guojian Pharmaceuticals Shanghai DND Pharm-Technology Shanghai Fosun Pharmaceutical Group Shanghai Furen Industrial Shanghai Institutes of Biological Sciences Shanghai Jinhe Bio-Technology Shanghai Pharmaceuticals Holding ShangPharma Shenzhen Heapalink Shenzhen Kangtai Biological Products Shenzhen Neptunus Bioengineering Shenzhen Salubris Pharmaceuticals Shenzhen Wenle ('Main Luck') Pharmaceutical Shijiazhuang Pharmaceutical Group Shijiazhuang Yiling Shineway Pharmaceutical Group Sichuan Jiufeng Pharmaceutical Sichuan Kelun Pharmaceutical Sichuan Kelun Pharmaceutical Sichuan Yuanda Shuyang Pharmaceutical Sihuan Pharmaceutical Holdings Simcere Pharmaceutical SiniWest Holdings Sino Biological Sino Biopharmaceutical Sinopharm State Key Lab of Respiratory Disease Sundia MediTech Sundiro Pharma Swiss Re Symbio Pharmaceuticals Takeda Tangshan Yian Bioengineering Tasly Pharmaceuticals Teva The Financial Times Thermo Fisher Scientific Tianjin Jin Yao Group Tianjin Kinnovata Pharmaceutical Company Tonghua Dongbao United Pharmatech Vectura Venturepharm Laboratories Vertex Pharmaceuticals Viva Biotech Wai Yuen Tong Medicine Holdings Walmart Holdings Wanbang Biopharmaceuticals Weigao Holding Winteam Pharmaceutical Group WuXi AppTec Xiamen Amoytop Biotech Xian-Janssen Pharmaceuticals Xiuzheng Pharmaceutical Xizang Haisco Yabao Pharmaceutical Group Yangtze River Pharmaceuticals Youcare Pharmaceutical Group Yunnan Baiyao Zai Lab Zendex Bio Strategy Zensun (Shanghai) Sci & Tech Zhejiang Beta Pharma Zhejiang Hisun Pharmaceutical Zhejiang Huahai Pharmaceutical Zhejiang Medicine Zhejiang Tianyuan Zhenjian Hisun Pharmaceuticals Zhuhai United States Labs Zuellig Pharma China
List of Organizations Mentioned in the Report China Food and Drug Administration (CFDA) China Academy of Chinese Medical Sciences Chinese Academy of Sciences (CAS) Chinese Center for Drug Evaluation Chinese Ministry of Commerce Diabetes Society Ministry of Commerce of the People's Republic of China Ministry of Health of the People's Republic of China Ministry of Labor and Social Security of the People's Republic of China National Development and Reform Commission National Institute for the Control of Pharmaceutical and Biological Products Northwest University Shandong University State Traditional Chinese Medicine Administration The World Bank University of Warwick US Food and Drug Administration Washington University WHO World Health Organization WTO World Trade Organization
Download sample pages
Complete the form below to download your free sample pages for Chinese Pharmaceutical Market Forecast 2017-2027
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.” Dr Luz Chapa Azuella, Mexico
Visiongain Publishes Deep Frozen Packaging Logistics Market Report 2023-2033
The global Deep Frozen Packaging Logistics market was valued at US$21,088.3 million in 2022 and is projected to grow at a CAGR of 7.7% during the forecast period 2023-2033.
Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033
The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.
The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.
The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
